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Abstract 
Selective sparing of organs at risk (OARs) adjacent to target volumes is feasible with newer 
radiotherapy techniques. The planning organ at risk volume (PRV) considers physiological 
movements and set-up inaccuracies of OARs. The objective of this study was to evaluate (peri-) 
ocular OAR shifts and derive PRVs. 
 
Dogs irradiated for periocular tumors with ≥4 cone-beam computed tomographies (CBCTs) used 
for position verification were retrospectively included. (Peri-)Ocular OARs were contoured on 
each CBCT and the systematic and random error of the shifts in relation to the planning CT 
position computed. The formula 1.3x∑+0.5x! was used to generate a PRV of each OAR.  
 
Thirty dogs were included, 450 OARs contoured, and 2145 shifts assessed. PRV expansion was 
different for each organ and 1-4mm for the dorsoventral and 1-2mm for both the mediolateral and 
craniocaudal axis. Since non-isotropic expansion is possible and more reasonable in OAR with 
directional shifts, a tailored PRV expansion can be chosen based on the calculations presented 
herein. 
 
Maximal PRV expansion was ≤4mm and directional for the majority. PRV estimates should be 
institution-specific and applied with caution, due to hard visualization on CBCTs. PRVs can help 
avoiding excessive radiation dose to ocular OARs. 
 
Keywords: eye, toxicity, canine 
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Zusammenfassung 
Die selektive Schonung von Risikoorganen (OARs) ist mit neueren Strahlentherapietechniken 
möglich. Das Planungsrisikoorgan-Volumen (PRV) berücksichtigt physiologische Bewegungen 
und Lagerungsungenauigkeiten von OARs. Ziel dieser Studie war es, (peri-)okulare OAR-
Verschiebungen zu bewerten und PRVs abzuleiten. 
Hunde, die aufgrund periokulärer Tumoren bestrahlt wurden und bei denen ≥4 Cone-Beam-
Computertomographien (CBCTs) zur Positionsüberprüfung verwendet wurden, wurden 
retrospektiv eingeschlossen. Die (peri-)okulären OARs wurden auf jedem CBCT konturiert und 
der systematische und zufällige Fehler der Verschiebungen in Bezug auf die Planungs-CT-
Position berechnet. Die Formel 1,3x∑+0,5x! wurde verwendet, um ein PRV für jedes OAR zu 
generieren.  
Dreißig Hunde wurden eingeschlossen, 450 OARs konturiert und 2145 Verschiebungen bewertet. 
Die PRV-Expansion war für jedes Organ unterschiedlich und betrug 1-4 mm für die 
dorsoventrale und 1-2 mm für die mediolaterale und kraniokaudale Achse.  
Die maximale PRV-Expansion war bei der Mehrheit ≤4mm und richtungsabhängig. PRV-
Schätzungen sollten einrichtungsspezifisch sein und aufgrund der schwierigen Visualisierung auf 
CBCTs mit Vorsicht angewendet werden. PRVs können helfen, eine übermäßige Strahlendosis 
für OARs zu vermeiden. 
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Abstract
Planning organ at risk volume (PRV) estimates have been reported as methods for
sparing organs at risk (OARs) during radiation therapy, especially for hypofractioned
and/or dose-escalatedprotocols. Theobjectives of this retrospective, analytical, obser-
vational study were to evaluate peri-ocular OAR shifts and derive PRVs in a sample
of dogs undergoing radiation therapy for periocular tumors. Inclusion criteria were as
follows: dogs irradiated for periocular tumors, with 3D-image-guidance and at least
four cone-beam CTs (CBCTs) used for position verification, and positioning in a rigid
bite block immobilization device. Peri-ocular OARswere contoured on each CBCT and
the systematic and random error of the shifts in relation to the planning CT position
computed. The formula 1.3×Σ+0.5xσ was used to generate a PRV of each OAR in the
dorsoventral, mediolateral, and craniocaudal axis. A total of 30 dogs were sampled,
with 450 OARs contoured, and 2145 shifts assessed. The PRV expansion was qual-
itatively different for each organ (1-4 mm for the dorsoventral and 1-2 mm for the
mediolateral and craniocaudal axes). Maximal PRV expansion was ≤4 mm and direc-
tional for the majority; most pronounced for corneas and retinas. Findings from the
current study may help improve awareness of and minimization of radiation dose in
peri-ocularOARs for future canine patients. Because someOARswere difficult to visu-
alize on CBCTs and/ or to delineate on the planning CT, authors recommend that PRV
estimates be institution-specific and applied with caution.
KEYWORDS
canine, eye, PRV, sinonasal, toxicity
1 INTRODUCTION
The planning organ at risk volume (PRV) gained more attention in the
ageof newer radiation techniques aiming at higher total doses or larger
Abbreviations: CBCT, cone-beam computed tomography; CTV, clinical target volume; GTV,
gross tumor volume; IMRT, intensity-modulated radiation therapy; kV, kilovolt; OAR, organ at
risk; PRV, planning organ at risk volume; PTV, planning target volume; RT, radiation therapy
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
© 2021 The Authors. Veterinary Radiology & Ultrasound published byWiley Periodicals LLC on behalf of American College of Veterinary Radiology
dose per fraction and thereby increasing the probability of damaging
organs at risk (OARs). AnOARor critical normal structure is normal tis-
suewhose radiation sensitivity canmarkedly influence treatment plan-
ning. It often lies in the very close vicinity of target volumes or even
within the high dose area. OARs are often mobile/ deformable struc-
tures. In addition, they are subject to similar setup inaccuracies as tar-
get volumes during radiation therapy (RT). To compensate for these
246 wileyonlinelibrary.com/journal/vru Vet Radiol Ultrasound. 2021;62:246–254.
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geometrical variations, a margin expansion is added to OARs, resulting
in the respective PRV.1 The PRV enables avoiding functional damage
in theOAR as it limits dose to specific, tolerated levels during the treat-
ment planning process. For sinonasal tumors in dogs,multiple PRVs can
be constructed for (peri-)ocular OARs such as globe, lens, as well as
optic nerve, chiasm, and lacrimal glands.
Before the age of newer radiation techniques in veterinary
medicine, moderate to severe damage to ocular structures was com-
mon, when treating sinonasal tumors in dogs, and could not be avoided
technically. This resulted in painful toxicities, often leading to (uni-
lateral) loss of vision, enucleation and other pathological changes.2
Nowadays, with intensity-modulated radiation therapy (IMRT), selec-
tive sparing of OARs is technically more feasible.3,4 In general, ocular
OARs are not strongly subject to large position changes during RT, but
ocular globes can rotate depending on anesthetic status.5 In dogs and
cats, a lens PRV has been calculated but it is not currently known how
other (peri-)ocular structures move during a course of RT.6
Objectives of the current studywere to evaluate translational shifts
of (peri-)ocular OARs during a course of RT with the goal of defining
PRVs in dogs for each (peri-)ocular structure in each axis. To meet this
goal, the formula derived by van Herk was used to calculate random
and systematic errors of shifts detectedbyon-board imaging fromdogs
treated for periocular tumors.7,8
2 METHODS
2.1 Case selection
The study was a retrospective, analytical, observational design. Com-
puted tomography (CT) datasets of client-owneddogs formerly treated
with RT for a neoplasia in the proximity of the eye at the Vetsuisse
Faculty of the University of Zurich during the period of January 2016
andDecember 2019were considered for inclusion. Sample size for the
study was based on convenience sampling. Datasets were included by
a board-certified veterinary radiation oncologist (V.M., Diplomate of
the American College of Veterinary Radiology [Radiation Oncology],
DACVR [RO]) if all OARs were included in CT images, if the institu-
tion’s rigid immobilization device had been used and the dog’s treat-
ment position verifiedwith at least four cone-beamCTs (CBCTs) during
a course of treatment. Information regarding signalment, tumor type
and locationwas collected frommedical records. All owners had signed
the hospital’s informed consent form stating their pet’s data could be
published anonymously.
2.2 Computed tomography and positioning
verification
As part of the inclusion criteria for the study, all dogs had undergone
a planning CT with the institution’s rigid patient positioning system
under general anesthesia for previous treatment. Magnetic resonance
imaging was not available. The positioning system consisted of an indi-
vidually shaped vacuum cushion (BlueBag BodyFix, Elekta AB, Stock-
holm, Sweden) supporting the thorax/ front legs and a custom-made
bite block (President The Original, Putty Soft, Coltène,Whaledent AG,
Altstaetten, Switzerland) supporting the upper jaw fixed on a poly-
carbonate tray on the treatment couch. Before each treatment, the
patient position was verified using daily 2D kilovolt (kV) orthogonal
digitally reconstructed radiographs and occasional kV-cone-beam CT
(CBCT). The treatment patient positioning was the same as for the
planningCT. For a 10-fraction-protocol, CBCTswere performedbefore
the 1./5./6./10. fraction as by our institution’s guidelines (except in case
ofmarkeddiscrepancy betweendigitally reconstructed radiograph and
CBCT). If a dog showed marked pitch or roll (which cannot be cor-
rected with our 4-degree of freedom treatment table), it was reposi-
tioned and imaging repeated.Definition ofmarked pitch/roll was based
on the attending radiation oncologist’s judgement, at our institution
interpreted as visible head nodding/movement when quick back and
forth switching of superimposed CT to CBCT images was performed. If
corrections of yaw, lateral, vertical or craniocaudal displacement were
noted, this was corrected online, the information used to correct the
table position before starting treatment (accepted treatment position
match) and used in the present contouring study. The final treatment
positions were confirmed by an experienced radiation therapist and/or
veterinary radiation oncologist. Details regarding CT/CBCT settings
were collected.
2.3 Contouring of organs at risk on planning
computed tomography
At the time of treatment planning for prior treatment of included dogs,
the planning CT images were imported into the External Beam Plan-
ning system (Eclipse™ Planning system, version 10.0.28 or 15.1.25;
Varian Oncology Systems, Palo Alto, California, USA). The contour-
ing workspace was used to delineate (peri-)ocular OARs on each plan-
ning CT. All OARs were converted to high resolution segment and the
OAR contouring guidelines for (a) ocular globe, (b) ocular lens, (c) optic
nerve, (d) optic chiasm, (e) retina (defined as “retina-choroid-sclera
complex”), and (f) lacrimal gland were used as previously described.9
The lens was contoured as hyperattenuating structure on the precon-
trast CT images. The lacrimal glands were contoured on post-contrast
images along the dorsolateral aspect of the globe deep to the orbital
ligament.10 To facilitate delineation of the “retina-choroid-sclera com-
plex,” a 1 mmmargin was contoured around the ocular globe, the crop
tool was used to crop the eye from the retina and the eraser tool was
used to erase by hand where the structure entered the cornea. (g) The
cornea – located rostral to the anterior chamber – was contoured sim-
ilarly except that the crop tool was also used to remove the part over-
lappingwith the retina.11 The distinction between the end of the retina
and the start of the cornea was not clearly visible and therefore a sub-
jective choice based on the presumed location of the iridocorneal angle
(with aid of the medial and lateral aspect of the lens) according to an
anatomical textbook.11 (h) The accessory lacrimal glands were con-
toured on post-contrast images located at the base of the vertical car-
tilage of the third eyelid.10 The volume of each periocular and ocular
structure was documented in mm3 using the measure 3D volume fea-
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ture in the external beam planning system. All of the contouring was
newly performed for this study by a veterinarian (F.W.), checked by
a board-certified veterinary radiation oncologist (V.M., DACVR[RO]),
and a consensus was reached.
2.4 Contouring of OARs on CBCTs for PRV
estimation
We used the online registration of each CBCT to the planning CT with
manual, computer-based adjustment of the dog’s actual position to
the aspired treatment position (with the planning CT as reference) in
the mediolateral, craniocaudal, and dorsoventral axis – as performed
for previous treatment (ie, no new, standardized registration was
performed). The observers were not aware of the shifts in position,
as all contours were delineated on the CBCT images. Some OARs
were difficult to address on the CBCT or were of different volume
if contoured from scratch (even if a change in volume of the organ
seemed very unlikely). This was due to a lack of contrast agent admin-
istration and/ or poorer image quality (in comparison to the diagnostic
images). We therefore created helper structures from the planning CT
ocular OARs to facilitate contouring them on the CBCTs: (a) Ocular
globe: The first helper structure consisted of the volume of the ocular
globe copied from the planning CT (EyeCBCT). This was repeated to
create one helper structure for each CBCT respectively (eg, EyeCBCT1,
EyeCBCT2, EyeCBCT3, EyeCBCT4). The transform structure tool was used
to shift (translational) this volume to match the appropriate position
in the co-registered CBCT. (b) Lens: The helper structure for the lens
consisted of the EyeCBCT minus the lens using the crop structure tool
(LensHelperCBCT). After adjusting the helper structure (eye minus
lens) to match the lens, we contoured the lens on the CBCT by using
the brush tool with the extra function of avoiding drawing over the
helper structure. A helper structure was used to facilitate contouring
and avoid underestimating the lens volume because the CBCT lens
structures were consistently smaller. This was most likely owed to
inferior (CB-)CT quality. (c) Optic nerves: The optic nerves were newly
contoured on each CBCT from the posterior aspect of the ocular globe
to the optic canal in the sphenoid bone. Because only the first third
of the optic nerve was visible on the CBCT after leaving the posterior
aspect of the ocular globe, we used the planning CT optic nerve as
guideline to create an optic nerve of similar size. (d) Optic chiasm:
The optic chiasm of the planning CT was copied for each CBCT and
adjusted for minimal changes of head position with the presphenoid
bone as a matching point. (e) Retinas and (g) corneas: Both structures
of the planning CT were duplicated for each CBCT and adapted to
the respective EyeCBCT structure with help of the transform structure
tool as described above. Again, the lens served as a guide for aligning
both structures to show the presumed location of the iridocorneal
angle. (f) Lacrimal glands: The lacrimal glands were not well visible
on unenhanced CBCT images (as described previously10) and were
therefore duplicated andmoved to the presumed CBCT position along
the dorsolateral aspect of the eye underneath the orbital ligamentwith
the transform structure tool. (h) Accessory lacrimal glands: Similarly,
the accessory lacrimal glands were not visible on CBCTs.10 A helper
structure consisting of the accessory lacrimal gland and part of the
bone in immediate proximity (using the segmentation wizard for bone
and choosing a field of view that included only the bone nearby) was
created. This helper structure was then adjusted to the CBCT with
the transform structure tool. The final CBCT accessory lacrimal gland
structure resulted from removal of the bone from the helper structure.
The volumes of all new CBCT OARs (excluding the ones contoured
with a helper structure or created with duplication) were measured in
mm3. The number of CBCTs per dog was documented, as well as the
number of fractions, total dose, and dose per fraction.
2.5 Establishing estimated planning organs at risk
volume
Due to online registration, the same coordination system was used for
OAR on the CBCT and planning CT. To assess the shifts, we therefore
retrieved the coordinates (in the dorsoventral, mediolateral, and cran-
iocaudal axis) of each ocular CBCT OAR on the planning CT using the
tool “move to isocenter of the structure” in the contouring workspace.
Those coordinates where then subtracted from the coordinates from
the same (reference) structure of the planning CT to reveal the shift in
millimeters (mm).
The formula 1.3×Σ + 0.5×σ for the calculation of the safety margin
proposed by van Herk et al. was used to evaluate the shifts of the OAR
on CBCTs compared to the planning CT position in the dorsoventral,
mediolateral, and craniocaudal axis.7,8 TheΣ represents the systematic
error and was calculated as the standard deviation of the mean shifts
of all dogs for all available CBCTs. The σ represents the random error
and was calculated as the quadratic summation of the standard devia-
tion of the shifts of each individual dog over the course of treatment.
Hence, the formula generated an estimated PRV of each OAR in each
axis separately for our population of dogs.
2.6 Statistical analysis
Statistical tests were selected and performed by two observers with
mathematical and clinical trial expertise. Data were coded in a spread-
sheet (Microsoft®, Excel for Mac, Version 16.43, Microsoft, Redmond,
WA98052-6399USA) and analyzedwith a commercial statistical soft-
ware package (IBM® SPSS® Statistics, Version 24, IBMCorp., Armonk,
New York). A graphical assessment and Shapiro-Wilk normality test
was performed on all data and mean ± standard deviation (SD) or
median and interquartile range (IQR) was reported, as appropriate.
Descriptive statistics such as mean and SD (for continuous variables
such as weight) and median and interquartile range for non-normally
distributed continuous variables (age, OARs) and absolute and relative
frequencies for discrete variables (sex, CBCTs) were computed by an
experienced veterinary radiation oncologist (C.R.B., DACVR[RO]), for-
mulas including systematic and random errors by an experiencedmed-
ical physicist (J.B.).
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3 RESULTS
3.1 Case characteristics
A total of 30 dogs were included in this study. The dogs presented
with different sinonasal (n = 23), maxillary (n = 3), and brain (n = 4,
olfactory bulb) neoplasia. Median age was 10.2 years (IQR 2.9, range
5.6-15.4 years). There were 12 neutered male, nine spayed female,
five intact male, and four intact female dogs. Both mixed breed
and purebred dogs were represented with most dogs (29/30) being
mesocephalic/dolichocephalic dogs and one dog (1/30) being brachy-
cephalic. Body weight ranged from 3.3 to 69.0 kg, with a mean of 24.6
(±14.6) kg.
3.2 Computed tomography and positioning
verification
A pre- and postcontrast standard CT scan of each dog was performed
with the same 16-slice CT scanner (Brilliance CT, Philips Health Care
Ltd, Best, theNetherlands) as previously described.12 Technical param-
eters for the CT scans are available in Supplementary file 1. Post-
contrast series were performed after intravenous administration of
2 ml/kg of contrast medium (Accupaque™, Iohexol, 350 mg I/mL,
osmality of 780mOsmol/kg, GE Healthcare AG, Switzerland) using a
power injector (Accutron CT-D, Med Tron, AG, Germany). For treat-
ment, a linear accelerator (Varian Clinac iX, Varian Medical Systems,
Palo Alto, USA) with a four degrees-of-freedom couch was used. All
CBCTs were performedwith the on-board imaging system (Varian On-
Board Imager®, Varian, Palo Alto, USA). Prior to treatment delivery,
a kV-CBCT was acquired and matched by a certified and experienced
radiation therapist. CBCT settings used in 25 cases were 100 kV (x-ray
tube voltage), 20 mA (x-ray tube current), 144mAs (exposure), 17.2 cm
scan length and full fan mode; a full 360◦ acquisition was used at
180◦/min. The maximum diameter for reconstruction was 250 mm;
512 × 512 pixels and a resolution of 0.488 mm. The CBCT settings
in five newer cases were 100 kV (x-ray tube voltage), 80 mA (x-ray
tube current), 1310mAs (exposure), 18 cm scan length and full fan fil-
ter; a full 360 acquisitionwas used at 180/min. Themaximumdiameter
for reconstruction was 100 mm; 512 × 512 pixels and a resolution of
0.195 mm. Quality assurance of the on-board imager was performed
as required by institutional and federal guidelines.13 The tests ensure
that the geometrical error of the CBCT acquisition and reconstruction
in addition to the error of the couch shift is within a 1mm tolerance.
All CBCT images were automatically imported into the treatment
planning system (Eclipse version 10.0.28 or 15.1.25, Varian Oncology
Systems, Palo Alto, USA) at their initial setup position, with 2 mm slice
spacing. The number of CBCTs performed and contoured per patient
was as follows: 4 (18 dogs), 5 (7 dogs), 6 (2 dogs), and 7, 8, or 9 CBCTs in
one dog each with a median of 4 (IQR 1, range 4–9). The median num-
ber of fractions, dose per fraction and total dose were 10 (IQR 0, range
10–18), 4.2 Gy (IQR 0.3, range 3–4.83 Gy), and 42 Gy (IQR 6.3, range
30–54Gy), respectively, administered with 6MV photons.
3.3 Ocular organs at risk on planning computed
tomography and cone-beam computed tomography
A total of 450 OARs were contoured on the planning CTs and 2145 on
CBCTs. An example case of a planning CT is shown in Figure 1A,B. The
volume of the ocular OARs is depicted in the Supporting Information
2 (except for CBCT structures where a template helper structure with
the same OAR size as in the planning CT was used). Optic chiasm vol-
ume was zero because export from the treatment planning system led
to very small volumes (<0.004mm3) that equaled zerowhen automatic
mathematical rounding was used.
3.4 Establishing estimated planning organs at risk
volume
A total of 2145 shifts were assessed. PRV expansion was different for
each organ and each axis with a range of 0.097-3.817 mm. An exam-
ple case is shown in Figure 2A,B. Since non-isotropic expansion is possi-
ble with contouring systems today and is more reasonable inOARwith
directional shifts, a tailored PRV expansion can be chosen based on the
calculations as presented in Table 1. For easier clinical implementation,
a rounded number per organ is shown in Table 2.
4 DISCUSSION
This study aimed at developing a PRV estimation for ocular structures
in dogs with use of our rigid positioning system. Almost two decades
ago, McKenzie et al. established a PRV formula to account for geomet-
ric uncertainties (random and systematic error) during the RT process.
This ensures that – despite geometric uncertainty – the dose in the
PRV as shown in the dose-volume-histogram is a better estimate of the
dose received by the OAR over the whole course of treatment com-
pared to the dose in the OAR volume alone. The systematic uncertain-
ties were rather large at that time because positioning was based on
lasers matched on the surface of the (prostate) cancer patient and no
daily image-guidance was performed.7 Nevertheless, the formula orig-
inally derived by van Herk is still in use today.6,8,14,15
At present, positioning errors can be corrected before each fraction
in human and more and more also in veterinary radiation facilities due
to frequent or even daily image-guidance with orthogonal radiographs
or CT. Subsequently, CBCT-guided RT and better positioning devices
led to a decrease in the systematic error and therefore smaller PTV
and PRV expansions.15–23 Smaller PTV expansions, advanced equip-
ment and treatment techniques led to conformal avoidance with the
possibility to use dose-escalated and/or more hypofractionated radia-
tion protocols in sinonasal and other tumors in dogs.4,9,24–28 Intensity-
modulated and volumetric-modulated arc RT allows the planner to
actively choose howmuch dose is deposited in a certain region. A steep
dose fall-off can be aspired close to an OAR with serial architecture
while allowing distribution of a lower dose to a larger amount of non-
critical normal tissue. Thus, more careful sculpting of (high) radiation
9
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F IGURE 1 A, Transverse and B, dorsal plane CT image of the head as imported into the treatment planning system (slice thickness 2mm, soft
tissue algorithm, 450/140windowwidth/level, sternal recumbency) at the level of the lenses (yellow) and eyes (green) showing the different
positions of theOARs from the planning CT and four CBCTs. Also seen: retina-sclera-complex (dark blue), cornea (violet), accessory and lacrimal
glands (light blue), optic nerve (pink) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Planning organ at risk volume expansionmargins of ocular organs at risk in sampled dogs








Ocular globe left 0.886 1.049 1.321
Ocular globe right 0.780 0.780 1.224
Lens left 1.493 1.342 1.726
Lens right 1.763 1.331 1.679
Optic nerve left 2.409 1.429 1.452
Optic nerve right 1.660 1.537 1.156
Optic chiasm 0.665 1.085 0.895
Retina left 1.416 1.141 1.265
Retina right 2.215 0.915 1.248
Cornea left 3.069 2.036 2.118
Cornea right 3.817 2.138 2.076
Lacrimal gland left 0.690 0.862 0.097







OARs: organs at risk, PRV: planning organ at risk volume.
dose around nearby OARs or PRV is of even greater importance today.
This is especially true for irradiation of sinonasal tumors to avoid possi-
bly debilitating late toxicity.2 As far as we know, only a PRV of the lens
but no other ocular or periocular structures exists for dogs.6
The present work described OAR contouring guidelines and a PRV
estimation for (peri-)ocular OARs when positioned in a custom-made
bite-block andmattress and treated with 3D-image-guided RT and use
of a 4-degree-of-freedom treatment table. Our PRV was based on the
10
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F IGURE 2 Three-dimensional-image of the right (on top) and left
eye (at the bottom) from the planning CTwith ocular globes (green),
corneas (yellow), retina-sclera-complex (purple), accessory lacrimal
glands (light pink), lacrimal glands (light orange), and optic nerves
(orange). Two additional optic nerve contours from twoCBCTs on each
side are shown in pink and turquoise to demonstrate small positional
shifts [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Estimated ocular planning organ at risk volume














Ocular globe 1 1 1-2
Lens 2 1-2 2
Optic nerve 2-3 2 1-2
Optic chiasm 1 1 1
Retina 2-3 1 1-2
Cornea 3-4 2 2




OARs: organs at risk, PRV: planning organ at risk volume.
shifts performed for actual treatment after CBCTs had been compared
with the reference planning CT images. We described a PRV in the
dorsoventral, mediolateral, and craniocaudal axis for the ocular globe,
ocular lens, optic nerve, optic chiasm, retina, cornea, lacrimal gland, and
accessory lacrimal gland based on 30 dogs.
Contouring of some ocular structures proved to be difficult, even
on diagnostic contrast-enhancedCT images. Transition between retina
and cornea is not easily visible even on diagnostic contrast-enhanced
images andwas therefore performed subjectively. To simplify contour-
ing and due to limitations of the contouring tools and visibility on CT
images, the retina and cornea were contoured outside the globe as
described above. This could have impacted the volumemeasurements,
andmay have influenced the PRV estimates. Accessory lacrimal glands
were not visible on unenhancedCBCTs and helper structures including
adjacent bone were used. This did not account for third eyelid move-
ment and made location dependent on bone and therefore positioning
errors and might therefore have underestimated true shifts. Magnetic
resonance imaging has been suggested for better identifying the optic
nerve but was not available for this population of dogs.29,30
Knowing the possible positions of the OARs during a treatment
course facilitates planning and sparing of OARs. This is especially
important when considering new simultaneously-integrated boost
treatments or stereotactic body radiation therapy as is emerg-
ing in veterinary radiation oncology and sinonasal irradiation at
present.9,24,25,27,31 A comparison of plans with and without PRV in
human nasal cavity and paranasal cancer patients showed equal target
dose coverage but a significant decrease in ocular OAR dose with help
of ocular PRVs.15
The PRV expansions in our study were very small in the majority of
OARs and directions with the exception of the ocular lens, optic nerve,
retina, and cornea. The ocular globe, and therefore the lens, retina,
and cornea can rotate, most likely explaining the larger PRV expan-
sions. This movement can for example change with depth of anesthe-
sia; however, this was not specifically assessed in the present study.5
Table 2 shows rounded PRV expansion margins for easier clinical use.
We included a range where applying mathematical rounding would
have led to a lower number, despite being rather in-between two num-
bers (i.e. 1–2 mm for the ocular globe for a value of 1.321 mm) as
more conservative (less risky) approach.With this range the reader can
decide if use of the smaller expansion margin (eg, if PTV and PRV are
overlapping) or rather use of the “safer,” larger expansionmargin (eg, if
PTVandPRVarewide apart) ismore appropriate. Becausewe included
only onebrachycephalic dog in our sample, it is possible that ourmargin
estimates may not be generalizable for brachycephalic breeds.
The PRV should not be mistaken for the true daily position of the
OAR as it considers different possible positions over a whole course
of treatment. Our study retrospectively looked at datasets with daily
imaging. However, only orthogonal kV radiographs were performed
daily; CBCTwas performed at least four times during a course of treat-
ment (i.e. for approximately every second to third fraction) and not
daily due to the retrospective nature of the study. Those CBCTs were
assumed to represent the possible shifts during the whole course of
treatment due to the rigidmaxillary dental mold and daily kV-kV imag-
ing with bone alignment; however, daily CBCT-imaging would have
been needed to verify this. While a PRV should influence treatment
planning and guide shaping of dose distribution, it should not lead to
target volume underdosage due to its inherent uncertainties. Under-
dosage of target volumes most likely leads to inferior tumor control
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as shown by tumor control probability models.32,33 Increasing accu-
racy/precision of patient positioning with resulting smaller target vol-
umes has therefore utmost priority, as OARs in close vicinity can be
sparedwith advanced techniques and sharp dose fall-off.4,34
A PRV of the lens has already been established in dogs.6 The lens is
exclusively sensitive already to low doses of radiation and cataract for-
mation can lead to loss of vision.2,35 Cataract formation is, however, a
non-life-threatening disease and can be treated with phacoemulsifica-
tion surgery to restore vision.36Otherocular andperiocular organs can
be subject to radiation-induced damage: keratitis, keratoconjunctivitis
sicca, retinal hemorrhage or glaucoma can occur and impair quality of
life or lead to vision impairment.2,37,38 Establishing a PRV not only for
the lens, but also for other periocular and ocular structures is an impor-
tant step towards future research including establishment of tolerance
doses.
In contrast to the study of Jafry et al, we decided to report our PRV
margins as individual expansionmargins in each axis in eachOAR.6 This
considers the directional shifts that aremore pronounced in oneor two
directions in someOARs, as shown for example in corneas and retinas.
Jafry et al used a similar rigid positioning device and reported a 3 mm
PRV expansion margin for the ocular lens. This is larger than our pro-
posed conservative estimate of 2 mm. It is important to point out that
– although similar – positioning devices might differ between institu-
tions. Jafry et al also performed new co-registrations with bone align-
ment at the level of the eyes and brain and did not use online regis-
tration previously used for treatment of the dogs, thereby eliminating
interobserver variability. Our approach more closely resembles daily
clinical routine: staff might change during a course of treatment or
alignment might be performed depending on the location of the tumor
(eg, rostral vs caudal). A prudent PRV of 2-3 mm might be considered
for the ocular lens in dogs for the future.
Different limitations should be addressed. The majority of dogs
included in our study underwent RT with 10 fractions, were daily
matchedwith orthogonal kV-imaging but only had four positioning ver-
ifications with CBCT over the course of treatment. For fractions with
2D orthogonal positioning verification only, roll displacements might
not have been displayed correctly.39 Looking at occasional 3D images
(CBCTs) only formatchingmight therefore not represent the trueOAR
displacementduring thewhole courseof treatment (ie, all 10 fractions).
The shifts detected could therefore be anunder- or overestimateof the
true daily shifts. In addition, with our equipment, displacements with
submillimeter accuracy or rotational errors (roll, pitch) were not cor-
rected due to on-board imagerwith 1mmprecision and a four degrees-
of-freedom couch. A six degrees-of-freedom couch would change ocu-
lar PRVs. However, not all human and only few veterinary facilities
report the use of image-guidance with a six degree-of-freedom couch
able to correct roll and pitch and achieving ≤0.5 mm positioning accu-
racy. Currently there is an ongoing controversial discussion in human
radiation oncology whether a six degree-of-freedom couch is neces-
sary for all patients or is for exampleonly clinically beneficial and there-
fore indicated for certain patients, such as for stereotactic radiother-
apyprotocols.40,41 Another limitationwas that thequality ofCT images
could have been affected by outside variables (eg, slice thickness, field
of view). In order to import CT images into the treatment planning sys-
tem, a reconstruction for RT is performed andmight include larger slice
thickness, thereby decreasing visibility of small ocular OAR and con-
touring accuracy. CBCT quality is inferior to a diagnostic helical CT
scan, and contrast agent highlighting certain structures is not routinely
administered for position verification.42,43 This was demonstrated by
both the accessory and lacrimal glands being invisible on the CBCTs
in our study. Also, the ocular globes were of different volume if con-
toured from scratch on the CBCT due to inferior visibility. We there-
fore created helper structures that either helped maintain the volume
of the OAR that should not change in between fractions (as in the ocu-
lar globe) or helped localize theOAR. Another limitationwas that some
OARs were difficult to contour. For example, MRI would have been
needed for more consistent delineation of the optic chiasm. This likely
influenced the size of optic chiasm PRV estimates. Another limitation
was that the same observer performed all measurements, therefore
interobserver variability was not assessed. Previous studies demon-
stratedmarked target volume andOAR contouring variations between
different human and veterinary radiation oncologists.44–46 These vari-
ations could also influence PRVs. Human radiation oncologists circum-
vented the lack of comprehensive identification and delineation of
OARs by a standardized delineation guide.47 Such a standardized sys-
tem would be of great advantage for veterinary radiation oncologists
in the future. Interobserver variability was minimized in our study by
all contours being delineated by one of the authors (FW) and checked
by a veterinary radiation oncologist (VM) asmentioned above. Another
limitationwas that the original treatment plans were selected and per-
formed by varying radiation oncologists. Contouring is not the only
step in RT that can vary between individuals, also the imagingmatching
process for positioning of patients can be different between different
radiation therapists or oncologists and depends on their experience.48
For a canine sinonasal tumor this could mean putting emphasis on a
perfect imaging match in the region of the eye ipsilateral to the tumor
orwith emphasis on amatch in the region of the olfactory bulb or there
could be a balance between the twodifferent possiblematching points.
Because our PRV was established from retrospective data, it was not
possible to determine the location of themost exact match.
In conclusion, the ocular PRV estimates described in this study –
with aid of a rigid positioning system and 3D-image guidance – may
help improve awareness of and minimization of dose in (peri-)ocular
OARs for future patients. Due to the limitationsmentioned above, PRV
estimates need to be implemented with caution and adapted to each
institution’s equipment. It remains to be elucidated if PRVs will lead to
ameasurable decrease in clinical ocular radiation toxicity in the future.
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